325 related articles for article (PubMed ID: 10087042)
1. Loperamide (ADL 2-1294), an opioid antihyperalgesic agent with peripheral selectivity.
DeHaven-Hudkins DL; Burgos LC; Cassel JA; Daubert JD; DeHaven RN; Mansson E; Nagasaka H; Yu G; Yaksh T
J Pharmacol Exp Ther; 1999 Apr; 289(1):494-502. PubMed ID: 10087042
[TBL] [Abstract][Full Text] [Related]
2. Nociceptive sensitivity and opioid antinociception and antihyperalgesia in Freund's adjuvant-induced arthritic male and female rats.
Cook CD; Nickerson MD
J Pharmacol Exp Ther; 2005 Apr; 313(1):449-59. PubMed ID: 15608071
[TBL] [Abstract][Full Text] [Related]
3. LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential.
Tao YM; Li QL; Zhang CF; Xu XJ; Chen J; Ju YW; Chi ZQ; Long YQ; Liu JG
Eur J Pharmacol; 2008 Apr; 584(2-3):306-11. PubMed ID: 18353307
[TBL] [Abstract][Full Text] [Related]
4. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
Zhao GM; Qian X; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
[TBL] [Abstract][Full Text] [Related]
5. JNJ-20788560 [9-(8-azabicyclo[3.2.1]oct-3-ylidene)-9H-xanthene-3-carboxylic acid diethylamide], a selective delta opioid receptor agonist, is a potent and efficacious antihyperalgesic agent that does not produce respiratory depression, pharmacologic tolerance, or physical dependence.
Codd EE; Carson JR; Colburn RW; Stone DJ; Van Besien CR; Zhang SP; Wade PR; Gallantine EL; Meert TF; Molino L; Pullan S; Razler CM; Dax SL; Flores CM
J Pharmacol Exp Ther; 2009 Apr; 329(1):241-51. PubMed ID: 19151246
[TBL] [Abstract][Full Text] [Related]
6. Antipruritic and antihyperalgesic actions of loperamide and analogs.
DeHaven-Hudkins DL; Cowan A; Cortes Burgos L; Daubert JD; Cassel JA; DeHaven RN; Kehner GB; Kumar V
Life Sci; 2002 Oct; 71(23):2787-96. PubMed ID: 12383884
[TBL] [Abstract][Full Text] [Related]
7. Peripheral effects of the kappa-opioid agonist EMD 61753 on pain and inflammation in rats and humans.
Machelska H; Pflüger M; Weber W; Piranvisseh-Völk M; Daubert JD; Dehaven R; Stein C
J Pharmacol Exp Ther; 1999 Jul; 290(1):354-61. PubMed ID: 10381799
[TBL] [Abstract][Full Text] [Related]
8. Local peripheral antinociceptive effects of 14-O-methyloxymorphone derivatives in inflammatory and neuropathic pain in the rat.
Obara I; Makuch W; Spetea M; Schütz J; Schmidhammer H; Przewlocki R; Przewlocka B
Eur J Pharmacol; 2007 Mar; 558(1-3):60-7. PubMed ID: 17204264
[TBL] [Abstract][Full Text] [Related]
9. Ring-constrained orvinols as analogs of buprenorphine: differences in opioid activity related to configuration of C(20) hydroxyl group.
Traynor JR; Guo L; Coop A; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1999 Dec; 291(3):1093-9. PubMed ID: 10565829
[TBL] [Abstract][Full Text] [Related]
10. Opioid peptide receptor studies. 17. Attenuation of chronic morphine effects after antisense oligodeoxynucleotide knock-down of RGS9 protein in cells expressing the cloned Mu opioid receptor.
Xu H; Wang X; Wang J; Rothman RB
Synapse; 2004 Jun; 52(3):209-17. PubMed ID: 15065220
[TBL] [Abstract][Full Text] [Related]
11. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
[TBL] [Abstract][Full Text] [Related]
12. DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted mu opioid agonist with antihyperalgesic activity: I. In vitro pharmacological characterization and pharmacokinetic properties.
Valenzano KJ; Miller W; Chen Z; Shan S; Crumley G; Victory SF; Davies E; Huang JC; Allie N; Nolan SJ; Rotshteyn Y; Kyle DJ; Broglé K
J Pharmacol Exp Ther; 2004 Aug; 310(2):783-92. PubMed ID: 15054115
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the antihyperalgesic action of a novel peripheral mu-opioid receptor agonist--loperamide.
Nozaki-Taguchi N; Yaksh TL
Anesthesiology; 1999 Jan; 90(1):225-34. PubMed ID: 9915332
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the peripheral and central effects of the opioid agonists loperamide and morphine in the formalin test in rats.
Shannon HE; Lutz EA
Neuropharmacology; 2002 Feb; 42(2):253-61. PubMed ID: 11804622
[TBL] [Abstract][Full Text] [Related]
15. The roles of different subtypes of opioid receptors in mediating the nucleus submedius opioid-evoked antiallodynia in a neuropathic pain model of rats.
Wang JY; Zhao M; Yuan YK; Fan GX; Jia H; Tang JS
Neuroscience; 2006; 138(4):1319-27. PubMed ID: 16472929
[TBL] [Abstract][Full Text] [Related]
16. Involvement of nitric oxide in the inhibition of bone cancer-induced hyperalgesia through the activation of peripheral opioid receptors in mice.
Menéndez L; Juárez L; García V; Hidalgo A; Baamonde A
Neuropharmacology; 2007 Jul; 53(1):71-80. PubMed ID: 17543351
[TBL] [Abstract][Full Text] [Related]
17. Evidence for a selective role of the delta-opioid agonist [8R-(4bS*,8aalpha,8abeta, 12bbeta)]7,10-Dimethyl-1-methoxy-11-(2-methylpropyl)oxycarbonyl 5,6,7,8,12,12b-hexahydro-(9H)-4,8-methanobenzofuro[3,2-e]pyrrolo[2,3-g]isoquinoline hydrochloride (SB-235863) in blocking hyperalgesia associated with inflammatory and neuropathic pain responses.
Petrillo P; Angelici O; Bingham S; Ficalora G; Garnier M; Zaratin PF; Petrone G; Pozzi O; Sbacchi M; Stean TO; Upton N; Dondio GM; Scheideler MA
J Pharmacol Exp Ther; 2003 Dec; 307(3):1079-89. PubMed ID: 14551288
[TBL] [Abstract][Full Text] [Related]
18. Peripherally mediated antinociception of the mu-opioid receptor agonist 2-[(4,5alpha-epoxy-3-hydroxy-14beta-methoxy-17-methylmorphinan-6beta-yl)amino]acetic acid (HS-731) after subcutaneous and oral administration in rats with carrageenan-induced hindpaw inflammation.
Bileviciute-Ljungar I; Spetea M; Guo Y; Schütz J; Windisch P; Schmidhammer H
J Pharmacol Exp Ther; 2006 Apr; 317(1):220-7. PubMed ID: 16339394
[TBL] [Abstract][Full Text] [Related]
19. Roles of different subtypes of opioid receptors in mediating the ventrolateral orbital cortex opioid-induced inhibition of mirror-neuropathic pain in the rat.
Zhao M; Wang JY; Jia H; Tang JS
Neuroscience; 2007 Feb; 144(4):1486-94. PubMed ID: 17184926
[TBL] [Abstract][Full Text] [Related]
20. Peripheral antinociceptive effects of mu- and delta-opioid receptor agonists in NOS2 and NOS1 knockout mice during chronic inflammatory pain.
Leánez S; Hervera A; Pol O
Eur J Pharmacol; 2009 Jan; 602(1):41-9. PubMed ID: 19041302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
